Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Chemed Corp can feel like tackling two companies at once: hospice care economics in VITAS and emergency plumbing metrics in Roto-Rooter. That split shows up in every 10-K footnote, Form 4 footnote, and 8-K headline, making Chemed’s SEC filings unusually dense.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Whether you need the latest Chemed quarterly earnings report 10-Q filing or want Chemed Form 4 insider transactions real-time, our platform surfaces the numbers and narrative in plain language. Instantly pinpoint hospice reimbursement rate disclosures, segment operating margins, and technician labor costs—without wading through hundreds of pages.
All Chemed filings arrive minutes after EDGAR posts. Click into:
- 10-K annual report—AI highlights VITAS patient census trends and Roto-Rooter service revenue (Chemed annual report 10-K simplified).
- 10-Q quarterly update—Compare sequential hospice margins with a one-click Chemed earnings report filing analysis.
- 8-K material events—Get alerts when Medicare rules change (Chemed 8-K material events explained).
- Form 4—Monitor executive stock moves, including CEO transactions (Chemed insider trading Form 4 transactions, Chemed executive stock transactions Form 4).
- Proxy statement (DEF 14A)—Understand how compensation aligns with both segments (Chemed proxy statement executive compensation).
Need context fast? Our summaries answer common questions like “understanding Chemed SEC documents with AI� or “where can I find Chemed’s hospice segment revenue?�. Save hours, stay informed, and make confident decisions with filings explained simply.
Chemed (CHE) Q2-25 10-Q highlights
- Consolidated revenue rose 3.9% YoY to $618.8 M, driven by 5.8% growth at VITAS ($396.2 M) and flat Roto-Rooter sales ($222.6 M).
- Net income fell 25.9% YoY to $52.5 M; operating margin compressed to 11.0% (vs 14.8%) as wage inflation and a $16.4 M Medicare cap adjustment weighed on VITAS.
- EPS dropped to $3.60 (-23%) despite a 3.4% lower share count; YTD EPS is $8.51 (-5%).
- Operating cash flow improved 5.7% to $171.4 M; cash balance climbed to $249.9 M (12/24: $178.4 M) after a $46.9 M OAS deposit was refunded following a favorable ALJ ruling.
- YTD treasury repurchases totaled $72.7 M (125k shares at $581.62 avg), leaving $182.6 M authorization.
- Balance sheet remains unlevered: $404.5 M revolver capacity available; leverage covenant 3.5Ă— vs actual <1Ă—.
- Small bolt-on acquisition: one Michigan Roto-Rooter franchise for $0.23 M; no material goodwill impact.
Segment mix: VITAS 64% of Q2 sales, 66% of segment operating profit; Roto-Rooter 36% of sales. Higher Medicare and labor costs pressured hospice margins, offset partly by solid plumbing and water-restoration demand. No guidance was provided.
Cel-Sci Corp. (CVM) filed a Form 4 showing CEO & Director Geert R. Kersten was granted 25,000 stock options on 07/28/2025. The options carry an $8.20 exercise price, expire 07/27/2035, and vest in three equal annual tranches starting one year from grant. No common-stock purchases or sales were reported in Table I.
After the grant, Kersten directly holds 175,157 derivative securities (options). The transaction represents routine equity compensation and introduces only immaterial dilution given Cel-Sci’s outstanding share base. The filing contains no financial results, guidance changes, or other corporate events.
Chemed Corporation (NYSE: CHE) filed a Form 8-K on June 27, 2025 to furnish a Regulation FD disclosure.
- Material event: The Company issued a press release (Exhibit 99) stating it now expects second-quarter 2025 earnings to be lower than previously anticipated and is reducing its full-year 2025 earnings guidance.
- The filing does not include specific dollar amounts, revised EPS figures or updated revenue ranges; only the direction of the change is disclosed.
- No other operational changes, financings, or acquisitions were reported in the filing.
- The press release itself is furnished, not filed, preserving safe-harbor protections for forward-looking statements.
Because the Company is signalling weaker performance and a downward revision to outlook, the disclosure is materially negative for investors, implying potential pressure on near-term financial results and valuation multiples. Investors will need to review the full press release and forthcoming Q2 results to quantify the impact.
FAQ
What is the current stock price of Chemed (CHE)?
What is the market cap of Chemed (CHE)?
What are the main business segments of Chemed Corp?
How does Chemed Corp generate its revenue?
What sets VITAS apart in the healthcare sector?
In what way is the Roto-Rooter segment positioned in the market?
How does Chemed Corp manage the challenges of operating in two distinct industries?
What competitive advantages does Chemed Corp maintain in its sectors?
Does Chemed Corp provide financial or investment advice?
How does the company ensure quality across its diverse business operations?
